Market capitalization | $45.19m |
Enterprise Value | $69.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.53 |
P/S ratio (TTM) P/S ratio | 4.91 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 187.45% |
Revenue (TTM) Revenue | $9.21m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a Verrica Pharmaceuticals Inc forecast:
5 Analysts have issued a Verrica Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 9.21 9.21 |
188%
188%
|
|
Gross Profit | 6.71 6.71 |
226%
226%
|
|
EBITDA | -74 -74 |
53%
53%
|
EBIT (Operating Income) EBIT | -75 -75 |
53%
53%
|
Net Profit | -85 -85 |
76%
76%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Head office | United States |
CEO | Jayson Rieger |
Employees | 100 |
Founded | 2013 |
Website | www.verrica.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.